logo
  

Pre-market Movers: SNAL, VS, OLMA, MTTR, HLTH…

us pre market 053119 11nov22 lt

The following are some of the stocks making big moves in Friday's pre-market trading (as of 07.00 A.M. ET).

In the Green

Snail, Inc. Class A Common Stock (SNAL) is up over 70% at $3.84
Versus Systems Inc. (VS) is up over 26% at $3.80
Olema Pharmaceuticals, Inc. (OLMA) is up over 23% at $4
Matterport, Inc. (MTTR) is up over 23% at $3.73
Cue Health Inc. (HLTH) is up over 20% at $4.95
Doximity, Inc. (DOCS) is up over 18% at $31.32
Gravity Co., Ltd. (GRVY) is up over 16% at $59.50
Primerica, Inc. (PRI) is up over 10% at $153.26
Prudential plc (PUK) is up over 9% at $23.85
KE Holdings Inc. (BEKE) is up over 8% at $12.32
ImmunoPrecise Antibodies Ltd. (IPA) is up over 8% at $5.51
SoundHound AI, Inc. (SOUN) is up over 7% at $2.03
Houston American Energy Corp. (HUSA) is up over 5% at $4.48

In the Red

Tattooed Chef, Inc. (TTCF) is down over 19% at $3.54
AirSculpt Technologies, Inc. (AIRS) is down over 18% at $3.85
Biohaven Ltd. (BHVN) is down over 11% at $14
FIGS, Inc. (FIGS) is down over 10% at $5.88
SeaStar Medical Holding Corporation (ICU) is down over 10% at $5.43
Silvergate Capital Corporation (SI) is down over 6% at $30.50
Invitae Corporation (NVTA) is down over 6% at $2.91
RELX PLC (RELX) is down over 5% at $26.31
Satixfy Communications Ltd. (SATX) is down over 5% at $10.90

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
The U.S. Consumer Product Safety Commission or CPSC announced recall of thousands of children's Robes made in China and sold exclusively on Amazon.com by various companies. The recalled robes fail to meet the federal flammability standards for children's sleepwear, posing a risk of burn injuries to children. Further, citing the same concerns, Paper Cape children's pajamas manufactured in Peru ... Health services company Cigna Corp. reported Friday higher profit in its fourth quarter reflecting growth in both Evernorth and Cigna Healthcare segments. Adjusted earnings and topline beat market estimates. Looking ahead for fiscal 2023, the company projects adjusted earnings and adjusted revenues to be higher than last year, but below market view. French drug major Sanofi SA reported Friday higher profit in its fourth quarter with strong revenue growth mainly with strong sales of Dupixent. Looking ahead for fiscal 2023, the company projects higher business earnings, but the expected growth is slower than recorded in fiscal 2022. Sanofi shares were losing around 4 percent in the morning trading in Paris as well as in pre-market activity...
RELATED NEWS
Follow RTT